readmission reduction intervention (ERþ) was associated with significantly reduced hospital readmissions compared to traditional ER alone (ERþ 5.9%, traditional ER 20.3%, p[0.017).
INTRODUCTION AND OBJECTIVES: Enhanced Recovery
After Surgery (ERAS) protocols are the new topic of interest among various surgical subspecialties. ERAS gives surgeons a dedicated pathway, no matter the surgeon or institution. Though treatment algorithms vary across specialties, the aim is identical: accelerate recovery time, thereby reducing the hospital length of stay. Within Urology, ERAS protocols are used with radical cystectomy patients. There is little evidence that looks at the application of ERAS protocol in renal surgery patients. We sought to implement an ERAS protocol in this patient population. The aim of this study is to report initial results.
METHODS: A retrospective analysis was performed comparing patients who underwent renal surgery prior to and after implementation of ERAS. The ERAS team is a multidisciplinary team composed of perioperative nurses, anesthesiologists and urologists. In the preoperative period, patients were given detailed instructions and expectations. On the morning of their surgery, they were provided with a standardized set of multimodal antiemetic and analgesic prophylactics, taking weight, GFR and type of surgery into consideration, and they remained on this pathway until discharge.
RESULTS: There were 76 patients in the pre-ERAS group and 42 in the ERAS group. Median length of stay (LOS) in the pre-ERAS vs ERAS group was 3 days vs 2 days (p<0.005). For open procedures, median LOS was 5 days vs 2 days (p<0.001). For robotic procedures, median LOS decreased from 3 days to 2 days (p<0.001). Median LOS was lower in the ERAS group independent of Age, Sex, BMI, ASA score and Anesthesia time. For the purposes of pain control analysis, all oral pain medications were converted to their oxycodone equivalent and all IV pain medications were converted to their morphine equivalent. Median total oxycodone went from 52.5mg to 8.75mg (p<0.005) and median total morphine went from 4mg to 0 (p<0.005). Thirty day readmission rate in the pre-ERAS group was 13.2% and 16.7% in the ERAS group (p [ 0.558). The average total cost per patient decreased from $23,379 pre-ERAS to $16,908 in the ERAS group. A NSQIP sampling of pre-state patients showed a complication rate of 18.9% and 17.4% in the ERAS group.
CONCLUSIONS: ERAS works well for renal surgery patients. It significantly decreased overall length of stay and hospital cost, without having a significant effect on readmission rate.
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MP15-19 COMPLICATIONS AFTER TRANSPERINEAL PROSTATE BIOPSY AMONG MEN WITH EMPLOYER-BASED INSURANCE COVERAGE
KC Biebighauser Bens*, Dattatraya Patil, Lauren Kipling, Mark Henry, Christopher Filson, Atlanta, GA INTRODUCTION AND OBJECTIVES: In response to rising risk of infectious complications following transrectal ultrasound guided prostate biopsies, advocates of transperineal prostate biopsy purport a near-zero risk of infectious complications and decreased need of periprocedural antibiotics compared to traditional transrectal prostate biopsy. This study aimed to evaluate the population-level incidence of complications after transperineal prostate biopsy.
METHODS: Using a database on employer-based private insurance claims, we identified men less than 65 years old who underwent transperineal prostate biopsy (CPT 55706) from 2009 -2015. Procedure and diagnosis codes were used to identify infectious, bleeding, and urinary retention complications associated with claims for hospitalization, emergency department (ED) and clinic visits within 30 days after transperineal prostate biopsy. Bivariate and multivariate analyses were performed to assess associations between outcomes of interest and pertinent patient covariates.
RESULTS: We identified 2,206 claims for transperineal prostate biopsy episodes. 45.8% of patients were between 60-64 years old, 31.7% between 55-59, and 22.4% less than 55 years old. 50% of biopsies were performed in the Southern region of the United States. Within 30 days of biopsy, 4.9% of patients visited the ED and 1.1% of patients were hospitalized. Across all settings (hospital, ED, and clinic visits) infectious complications occurred in 4.7% of patients and urinary retention in 7.4% of patients. Overall, 2.3% of the episodes required
